Mar 10, 2021

Featuring an interview with Dr Joseph Mikhael on the following topics:

• Recently approved agents for multiple myeloma (MM) (0:00)
• Case: A man in his mid-70s with standard-risk MM receives isatuximab with pomalidomide and dexamethasone as second-line therapy (22:15)
• Case: A woman in her mid-70s with high-risk MM receives selinexor and dexamethasone after disease progression on multiple lines of therapy (24:01)
• Case: A woman in her late 60s experiences keratopathy after treatment with belantamab mafodotin for relapsed/refractory MM (25:31)
• Consideration of transplant for patients with MM; DREAMM-6 trial evaluating belantamab mafodotin with bortezomib/dexamethasone for relapsed/refractory MM (27:16)

CME information and select publications